Effect of Preventive PCI for Non-Flow-Limiting Vulnerable Plaques in Patients With Diabetes: The PREVENT Trial
The PREVENT trial demonstrated that among patients with non-flow-limiting vulnerable plaques, preventive percutaneous coronary intervention (PCI) reduced the risk of the 2-year primary endpoint—comprising cardiac death, target vessel–related myocardial infarction, ischemia-driven target vessel revascularization, and hospitalization for unstable angina or progressive angina—compared with optimal medical therapy (OMT) alone, regardless of diabetes status, Dr. Min Chul Kim and colleagues, Chonnam National University Hospital, Korea, reported in the August 21 issue of European Heart Journal.
- Free Registration
-
Already have an account?Log In
A portal site of complex catheter intervention techniques
TCROSS NEWS Global is an online medical journal that provides
valuable information on Cardiovascular medicine to medical professionals
worldwide.
We bring you the latest findings and trends in all areas of
cardiovascular medicine. Please register and subscribe for unlimited access to
quality Cardiovascular News!
We provide timely and up-to-date information to our partners across the world by covering and reporting live sessions and conferences, featuring of complex cases, newsletters, academic researches and case studies.
Recommendations
